Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Mar;79(7-8):1162–1167. doi: 10.1038/sj.bjc.6690185

The association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patients

E Reyes 1, J Carballido 2, L Manzano 1, L Moltó 1, C Olivier 2, M Alvarez-Mon 1
PMCID: PMC2362230  PMID: 10098752

Abstract

We investigated the potential existence of differences in the distribution of T-lymphocyte subsets and in the proliferative response of these CD2+ cells to polyclonal mitogens in patients with transitional cell bladder carcinoma (SBTCC) treated with prophylactic intracavitary instillations of bacillus Calmette–Guérin (BCG) according to their clinical response to this treatment. Before BCG treatment, different subset distribution (CD8+ and CD3+ CD56+), activation antigen expression (CD3+ HLA– DR+) and proliferative response to mitogenic signals were found in CD2+ cells from SBTCC patients prophylactically treated with BCG who remained free of disease or those who had recurrence of tumour. Otherwise, the prophylactic intracavitary BCG instillations in SBTCC patients are associated with a transitory variation of T-lymphocyte subset distribution (CD4 and CD8) and activation antigens expression (CD25). © 1999 Cancer Research Campaign

Keywords: bladder neoplasm, BCG, immunotherapy, T-lymphocytes, recurrence

Full Text

The Full Text of this article is available as a PDF (102.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Carballido J., Alvarez-Mon M., Olivier C., Moltó L. Inmunoterapia de las neoplasias uroteliales. Implicaciones experimentales y clínicas del interferón alfa. Arch Esp Urol. 1990;43 (Suppl 2):149–158. [PubMed] [Google Scholar]
  2. Esrig D., Freeman J. A., Stein J. P., Skinner D. G. Early cystectomy for clinical stage T1 transitional cell carcinoma of the bladder. Semin Urol Oncol. 1997 Aug;15(3):154–160. [PubMed] [Google Scholar]
  3. Hermann G. G., Petersen K. R., Steven K., Zeuthen J. Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: decreased LAK cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cells. J Clin Immunol. 1990 Nov;10(6):311–320. doi: 10.1007/BF00917476. [DOI] [PubMed] [Google Scholar]
  4. Hurle R., Losa A., Ranieri A., Graziotti P., Lembo A. Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy. J Urol. 1996 Nov;156(5):1602–1605. [PubMed] [Google Scholar]
  5. Jackson A. M., Alexandroff A. B., Kelly R. W., Skibinska A., Esuvaranathan K., Prescott S., Chisholm G. D., James K. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy. Clin Exp Immunol. 1995 Mar;99(3):369–375. doi: 10.1111/j.1365-2249.1995.tb05560.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Jackson A. M., Alexandroff A. B., McIntyre M., Esuvaranathan K., James K., Chisholm G. D. Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy. J Clin Pathol. 1994 Apr;47(4):309–312. doi: 10.1136/jcp.47.4.309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kaempfer R., Gerez L., Farbstein H., Madar L., Hirschman O., Nussinovich R., Shapiro A. Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J Clin Oncol. 1996 Jun;14(6):1778–1786. doi: 10.1200/JCO.1996.14.6.1778. [DOI] [PubMed] [Google Scholar]
  8. Kurth K., Tunn U., Ay R., Schröder F. H., Pavone-Macaluso M., Debruyne F., ten Kate F., de Pauw M., Sylvester R. Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. J Urol. 1997 Aug;158(2):378–384. doi: 10.1016/s0022-5347(01)64484-7. [DOI] [PubMed] [Google Scholar]
  9. Lapham R. L., Ro J. Y., Staerkel G. A., Ayala A. G. Pathology of transitional cell carcinoma of the bladder and its clinical implications. Semin Surg Oncol. 1997 Sep-Oct;13(5):307–318. doi: 10.1002/(sici)1098-2388(199709/10)13:5<307::aid-ssu4>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  10. Larsson E. L., Iscove N. N., Coutinho A. Two distinct factors are required for induction of T-cell growth. Nature. 1980 Feb 14;283(5748):664–666. doi: 10.1038/283664a0. [DOI] [PubMed] [Google Scholar]
  11. Mack D., Frick J. Five-year results of a phase II study with low-dose bacille Calmette-Guerin therapy in high-risk superficial bladder cancer. Urology. 1995 Jun;45(6):958–961. doi: 10.1016/s0090-4295(99)80115-0. [DOI] [PubMed] [Google Scholar]
  12. Madsen M., Johnsen H. E., Hansen P. W., Christiansen S. E. Isolation of human T and B lymphocytes by E-rosette gradient centrifugation. Characterization of the isolated subpopulations. J Immunol Methods. 1980;33(4):323–336. doi: 10.1016/0022-1759(80)90003-4. [DOI] [PubMed] [Google Scholar]
  13. Moltó L., Carballido J., Manzano L., Reyes E., Olivier C., Alvarez-Mon M. Prophylactic intracavitary treatment with interferon alpha increases interferon gamma production by peripheral blood mononuclear cells in patients with superficial transitional cell carcinoma of the bladder. Br J Cancer. 1997;75(12):1849–1853. doi: 10.1038/bjc.1997.315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Nadler R. B., Catalona W. J., Hudson M. A., Ratliff T. L. Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J Urol. 1994 Aug;152(2 Pt 1):367–373. doi: 10.1016/s0022-5347(17)32741-6. [DOI] [PubMed] [Google Scholar]
  15. Niks M., Otto M., Busová B., Stefanovic J. Quantification of proliferative and suppressive responses of human T lymphocytes following ConA stimulation. J Immunol Methods. 1990 Feb 9;126(2):263–271. doi: 10.1016/0022-1759(90)90159-s. [DOI] [PubMed] [Google Scholar]
  16. O'Donnell M. A., DeWolf W. C. Bacillus Calmette-Guérin immunotherapy for superficial bladder cancer. New prospects for an old warhorse. Surg Oncol Clin N Am. 1995 Apr;4(2):189–202. [PubMed] [Google Scholar]
  17. Pansadoro V., Emiliozzi P., Defidio L., Donadio D., Florio A., Maurelli S., Lauretti S., Sternberg C. N. Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results. J Urol. 1995 Dec;154(6):2054–2058. [PubMed] [Google Scholar]
  18. Patard J. J., Chopin D. K., Boccon-Gibod L. Mechanisms of action of bacillus Calmette-Guérin in the treatment of superficial bladder cancer. World J Urol. 1993;11(3):165–168. doi: 10.1007/BF00211413. [DOI] [PubMed] [Google Scholar]
  19. Picker L. J., Terstappen L. W., Rott L. S., Streeter P. R., Stein H., Butcher E. C. Differential expression of homing-associated adhesion molecules by T cell subsets in man. J Immunol. 1990 Nov 15;145(10):3247–3255. [PubMed] [Google Scholar]
  20. Prescott S., James K., Hargreave T. B., Chisholm G. D., Smyth J. F. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol. 1992 Jun;147(6):1636–1642. doi: 10.1016/s0022-5347(17)37668-1. [DOI] [PubMed] [Google Scholar]
  21. Pryor K., Goddard J., Goldstein D., Stricker P., Russell P., Golovsky D., Penny R. Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing. Br J Cancer. 1995 Apr;71(4):801–807. doi: 10.1038/bjc.1995.155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ratliff T. L., Ritchey J. K., Yuan J. J., Andriole G. L., Catalona W. J. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol. 1993 Sep;150(3):1018–1023. doi: 10.1016/s0022-5347(17)35678-1. [DOI] [PubMed] [Google Scholar]
  23. Rosenbaum R. S., Park M. C., Fleischmann J. Intravesical bacille Calmette-Guérin therapy for muscle invasive bladder cancer. Urology. 1996 Feb;47(2):208–211. doi: 10.1016/S0090-4295(99)80418-X. [DOI] [PubMed] [Google Scholar]
  24. Satoh M., Seki S., Hashimoto W., Ogasawara K., Kobayashi T., Kumagai K., Matsuno S., Takeda K. Cytotoxic gammadelta or alphabeta T cells with a natural killer cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2. J Immunol. 1996 Nov 1;157(9):3886–3892. [PubMed] [Google Scholar]
  25. Takashi M., Wakai K., Ohno Y., Murase T., Miyake K. Evaluation of a low-dose intravesical bacillus Calmette-Guérin (Tokyo strain) therapy for superficial bladder cancer. Int Urol Nephrol. 1995;27(6):723–733. doi: 10.1007/BF02552138. [DOI] [PubMed] [Google Scholar]
  26. Thanhäuser A., Böhle A., Schneider B., Reiling N., Mattern T., Ernst M., Flad H. D., Ulmer A. J. The induction of bacillus-Calmette-Guérin-activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol Immunother. 1995 Feb;40(2):103–108. doi: 10.1007/BF01520291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Turner J., Dockrell H. M. Stimulation of human peripheral blood mononuclear cells with live Mycobacterium bovis BCG activates cytolytic CD8+ T cells in vitro. Immunology. 1996 Mar;87(3):339–342. doi: 10.1046/j.1365-2567.1996.512590.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Verhagen A., Mackay I. R., Rowley M., Tymms M. Comparison of augmentation of human natural killer cell cytotoxicity by interferon-alpha subtypes. Nat Immun Cell Growth Regul. 1990;9(5):325–333. [PubMed] [Google Scholar]
  29. Walker P. R., Ohteki T., Lopez J. A., MacDonald H. R., Maryanski J. L. Distinct phenotypes of antigen-selected CD8 T cells emerge at different stages of an in vivo immune response. J Immunol. 1995 Oct 1;155(7):3443–3452. [PubMed] [Google Scholar]
  30. Witjes J. A. Current recommendations for the management of bladder cancer. Drug therapy. Drugs. 1997 Mar;53(3):404–414. doi: 10.2165/00003495-199753030-00005. [DOI] [PubMed] [Google Scholar]
  31. de Reijke T. M., de Boer E. C., Kurth K. H., Schamhart D. H. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol. 1996 Feb;155(2):477–482. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES